Efficacy and safety of pubertal induction using 17β-estradiol in transgirls
| Autor: | Peggy T. Cohen-Kettenis, Sebastian E.E. Schagen, Henriette A. Delemarre-van de Waal, Sabine E. Hannema |
|---|---|
| Přispěvatelé: | Amsterdam Gastroenterology Endocrinology Metabolism, Medical psychology, Pediatrics |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Adolescent medicine.drug_class Endocrinology Diabetes and Metabolism Clinical Biochemistry Blood Pressure 030209 endocrinology & metabolism Context (language use) Hematocrit Biochemistry Drug Administration Schedule Statistics Nonparametric 03 medical and health sciences 0302 clinical medicine Endocrinology 030225 pediatrics Ethinylestradiol Internal medicine Humans Medicine Sexual Maturation Physical Examination Sex Characteristics Breast development Dose-Response Relationship Drug Estradiol medicine.diagnostic_test business.industry Puberty Biochemistry (medical) Gender Identity Bone age Body Height Treatment Outcome Estrogen Body Composition Lean body mass Female business Body mass index Blood Chemical Analysis Follow-Up Studies medicine.drug |
| Zdroj: | Hannema, S E, Schagen, S E E, Cohen-Kettenis, P T & Delemarre-Van De Waal, H A 2017, ' Efficacy and safety of pubertal induction using 17β-estradiol in transgirls ', Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 7, pp. 2356-2363 . https://doi.org/10.1210/jc.2017-00373 The Journal of clinical endocrinology and metabolism, 102(7), 2356-2363. The Endocrine Society Journal of Clinical Endocrinology and Metabolism, 102(7), 2356-2363 Journal of Clinical Endocrinology and Metabolism, 102(7), 2356-2363. The Endocrine Society |
| ISSN: | 0021-972X |
| DOI: | 10.1210/jc.2017-00373 |
| Popis: | Context: Puberty suppression using gonadotropin-releasing hormone agonists, followed by induc tion of the desired sex characteristics using sex steroids, has been recommended by the current guidelines as the treatment of choice for gender dysphoric adolescents, although little evidence is available. Aim: To evaluate the efficacy and safety of estrogen treatment for pubertal induction in transgirls (female-identifying adolescents assigned male at birth). Methods: Twenty-eight adolescents treated with oral estrogen for 1 year were included. The Tanner stage, anthropometry, laboratory parameters, bone age, and body composition were evaluated. Results: Breast development started within 3 months in 83% of adolescents, and after 3 years, 86% had Tanner breast stage 4 to 5. The hip circumference increased and the waist/hip ratio decreased. The median serum estradiol was 100 pmol/L (range, 24 to 380) at the standard adult dose of 2mg of 17b-estradiol. The adult height standard deviation score was +1.9 (for females). The body mass index standard deviation score, lean body mass percentage, fat percentage, and blood pressure did not change. No abnormalities of creatinine or liver enzymes were detected, and the hematocrit and hemoglobin A1c did not change. One individual developed hyperprolactinemia during high-dose ethinylestradiol treatment to limit growth. Conclusions: Pubertal induction using estradiol is effective; however, an adult dose of 2mg does not always result in appropriate serum estradiol levels. Monitoring renal function, liver enzymes, hematocrit, and hemoglobin A1c during pubertal induction with estradiol is not necessary. Further studies are needed to establish effective and safe methods to limit growth. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|